Skip to main content

Grifols S.A. (GRFS)

NASDAQ: GRFS · IEX Real-Time Price · USD
13.87 0.05 (0.36%)
Oct 21, 2021 4:00 PM EDT - Market closed
Market Cap13.57B
Revenue (ttm)6.51B
Net Income (ttm)754.32M
Shares Out687.56M
EPS (ttm)0.56
PE Ratio24.64
Forward PE10.24
Dividend$0.46 (3.29%)
Ex-Dividend DateJun 3, 2021
Volume294,150
Open13.80
Previous Close13.82
Day's Range13.62 - 13.98
52-Week Range13.53 - 19.95
Beta0.10
AnalystsBuy
Price Target22.20 (+60.1%)
Est. Earnings DateNov 4, 2021

About GRFS

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others segments. The Bioscience segment produces plasma-derived medicines for the treatment of rare, chronic, and life-threatening conditions. It offers intravenous immunoglobin, albumin, alpha-1-antitrypsin, factor VIII, antithrombin, and other specialty hyperimmune immunoglobulins. The Hospital segment offers non-biological pharmaceutica...

IndustryBiotechnology
IPO DateMay 17, 2006
Employees23,431
Stock ExchangeNASDAQ
Ticker SymbolGRFS
Full Company Profile

Financial Performance

In 2020, Grifols S.A.'s revenue was 5.34 billion, an increase of 4.73% compared to the previous year's 5.10 billion. Earnings were 618.55 million, a decrease of -1.06%.

Financial numbers in millions EURFinancial Statements

Analyst Forecast

According to 4 analysts, the average rating for Grifols S.A. stock is "Buy." The 12-month stock price forecast is 22.20, which is an increase of 60.06% from the latest price.

Price Target
$22.20
(60.06% upside)
Analyst Consensus: Buy

News

Grifols and Egypt inaugurate first African plasma-supply platform, in Cairo, as part of the alliance to attain self-s...

BARCELONA, Spain, Oct. 19, 2021 /PRNewswire/ -- Grifols (MCE:GRF) (MCE:GRF.P) (NASDAQ:GRFS), one of the world's leading producers of plasma-derived medicines with a more than 110-year track record of co...

2 days ago - PRNewsWire

New Strong Sell Stocks for September 22nd

MANU, GRFS, IMCC, and INTZ have been added to the Zacks Rank #5 (Strong Sell) List on September 22, 2021

Other symbols:IMCCINTZMANU
4 weeks ago - Zacks Investment Research

Grifols Sells Off With Effects of Pandemic

Spain-based biotech Grifols SA ( GRFS , Financial) is trading low due to the effects of the pandemic on sales and revenue. The company is completely vertically integrated in the plasma business.

1 month ago - GuruFocus

Moving Average Crossover Alert: Grifols (GRFS)

Grifols (GRFS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

3 months ago - Zacks Investment Research

Singapore's sovereign fund invests $1 billion in Grifols's U.S. unit

Singapore's wealth fund GIC agreed to invest around 1 billion dollars in Biomat, a U.S.-based plasma collection company owned by Grifols, thus becoming a strategic investor in the Spanish pharmaceutical...

3 months ago - Reuters

Grifols introduces HyperHEP B® (hepatitis B immune globulin [human]), a new formulation to treat patients exposed to ...

BARCELONA, Spain, June 1, 2021 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a leading global producer of plasma-derived medicines and provider of a variety of postexposure prophylax...

4 months ago - PRNewsWire

Grifols takes another step in the fight against Alzheimer's, partners with Ace to open first AMBAR® Center in Barcelona

The center will collect real-world data on AMBAR® clinical program - AMBAR® Center combines Grifols' more than 15 years of knowledge researching this devastating disease with the experience of the non-p...

5 months ago - PRNewsWire

Grifols and Andorran government will establish world-class immunology research hub to expand global knowledge of the ...

BARCELONA, Spain, April 28, 2021 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a leading global producer of plasma-derived medicines with a history of more than 110 years contributin...

5 months ago - PRNewsWire

5 Profitable Stocks With a Margin of Safety

According to the GuruFocus discounted cash flow calculator as of April 21, the following companies have a high margin of safety and have grown their margins over a 10-year period.

Other symbols:AOSCBOEICLRMPW
6 months ago - GuruFocus

Grifols Extends Commitment to World Federation of Hemophilia Humanitarian Aid Program to 2030

BARCELONA, Spain, April 15, 2021   /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived medicines with a track record of more than 100 years...

6 months ago - PRNewsWire

Grifols 2020 Annual Report on Form 20-F filed with the SEC on April 9, 2021

BARCELONA, Spain, April 9, 2021 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF), (MCE: GRF.P) and (NASDAQ: GRFS) announced that it has filed its 2020 Annual Report on Form 20-F with the United Stat...

6 months ago - PRNewsWire

Grifols announces topline data from NIAID Phase 3 ITAC trial (INSIGHT-013) evaluating hyperimmune globulins as a trea...

BARCELONA, Spain, April 2, 2021 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived medicines with a track record of more than 100 years de...

6 months ago - PRNewsWire

Grifols installs first-ever DG Reader Net analyzer in North America

BARCELONA, Spain, March 22, 2021 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived therapies and leader in the development of innovative ...

6 months ago - PRNewsWire

Grifols reinforces its innovation strategy after completing the acquisition of GigaGen to boost a novel method to gen...

BARCELONA, Spain, March 9, 2021 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P; NASDAQ: GRFS), a global healthcare company with a proven track record of more than 100 years dedicated to improving the hea...

7 months ago - PRNewsWire

Moving Average Crossover Alert: Grifols

Grifols (GRFS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

7 months ago - Zacks Investment Research

Is Grifols (GRFS) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest v...

8 months ago - Zacks Investment Research

GRFS vs. ZTS: Which Stock Is the Better Value Option?

GRFS vs. ZTS: Which Stock Is the Better Value Option?

Other symbols:ZTS
8 months ago - Zacks Investment Research

Grifols (GRFS) to Begin Study on Plasma-Derived COVID-19 Drug

Grifols (GRFS) to begin a study in Spain to evaluate a plasma-derived medicine that would provide immediate immunity against COVID-19.

9 months ago - Zacks Investment Research

Grifols begins clinical trial of a new treatment that would provide immediate immunity against COVID-19

BARCELONA, Spain, Jan. 18, 2021 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of therapies with plasma-derived proteins with a track record of more tha...

9 months ago - PRNewsWire

GRFS or ZTS: Which Is the Better Value Stock Right Now?

GRFS vs. ZTS: Which Stock Is the Better Value Option?

Other symbols:ZTS
9 months ago - Zacks Investment Research

Portfolio Manager Diary: Contrast The Information Obtained By The Company Management Before Investing

Good prospects for the global immunoglobulin business. Koru Medical's strategic plan is to reach $ 50M in sales by 2022, a gross margin of 70%, and organic and annual sales growth of + 20%.

9 months ago - Seeking Alpha

Should Value Investors Consider Grifols (GRFS) Stock Now?

Let's see if Grifols (GRFS) stock is a good choice for value-oriented investors right now from multiple angles.

11 months ago - Zacks Investment Research

The Dow Jones Sustainability Index recognizes Grifols as one of the world's most sustainable companies

BARCELONA, Spain, Nov. 16, 2020 /PRNewswire/ -- Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global healthcare company and one of the world's leading producers of plasma-derived medicines with more...

11 months ago - PRNewsWire

Grifols partners with TRC Healthcare to streamline intravenous compounding education

BARCELONA, Spain, Nov. 12, 2020 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived therapies and provider of technologies and services for...

11 months ago - PRNewsWire

Grifols Class B: Buy The Recovery In The U.S. Plasma Business

Oligopoly of four companies that control more than 80% of the plasma business. Secular growth trend for population aging.

11 months ago - Seeking Alpha